Statements (57)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:Company
|
| gptkbp:acquisition |
gptkb:Myriad_RBM
SOPHi A GENETICS |
| gptkbp:awards |
Best Places to Work
Innovative Company Award Top 100 Biotech Companies |
| gptkbp:ceo |
Paul Diaz
|
| gptkbp:clinical_trial |
BRCA testing
Bladder cancer testing Breast cancer testing Colorectal cancer testing Endometrial cancer testing Hematologic malignancies testing Kidney cancer testing Lung cancer testing Melanoma testing Ovarian cancer testing Pancreatic cancer testing Prostate cancer testing Thyroid cancer testing |
| gptkbp:employees |
~1,000
|
| gptkbp:focus_area |
Cancer treatment
Precision medicine Pharmacogenomics Rare diseases Genomic testing |
| gptkbp:founded |
gptkb:1996
|
| gptkbp:headquarters |
gptkb:Cambridge,_Massachusetts
|
| https://www.w3.org/2000/01/rdf-schema#label |
MYGN
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:key_people |
David Schenkein
|
| gptkbp:partnership |
gptkb:Merck
gptkb:Astra_Zeneca gptkb:Bristol-Myers_Squibb gptkb:Pfizer gptkb:Novartis |
| gptkbp:products |
Genetic testing
|
| gptkbp:research_focus |
gptkb:Oncology
gptkb:Melanoma gptkb:Colorectal_cancer gptkb:Endometrial_cancer Breast cancer Lung cancer Prostate cancer Pancreatic cancer Bladder cancer Hematologic malignancies Thyroid cancer Kidney cancer |
| gptkbp:revenue |
$500 million (2022)
|
| gptkbp:services |
Oncology diagnostics
|
| gptkbp:stock_symbol |
gptkb:MYGN
|
| gptkbp:subsidiary |
gptkb:Myriad_Women's_Health
Myriad Genetics Laboratories |
| gptkbp:website |
www.myriad.com
|
| gptkbp:bfsParent |
gptkb:Myriad_Genetics
|
| gptkbp:bfsLayer |
6
|